Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494924 | 0.85 | MET (0.53) | METMMP13CYP3A4PRKACGPIK3CD | |
| SCHEMBL2698465 | 0.65 | MET (0.68) | MET | |
| SCHEMBL2493581 | 0.65 | MET (0.82) | MET | |
| SCHEMBL2495079 | 0.64 | MET (0.72) | MET | |
| SCHEMBL2494716 | 0.64 | MMP13 (0.64) | RAB9AMMP13SLC22A8 | |
| SCHEMBL2494603 | 0.62 | MET (0.63) | MET | |
| SCHEMBL2698870 | 0.62 | MET (1.00) | METCYP3A4PRKACG | |
| SCHEMBL9910360 | 0.62 | MET (1.00) | METCYP3A4PRKACG | |
| SCHEMBL2494650 | 0.62 | MMP13 (0.68) | RAB9AMMP13SLC22A8 | |
| SCHEMBL2499849 | 0.61 | MMP13 (0.60) | RAB9AMMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MET 2/4885RAB9A 1750/4885MMP13 4308/4885 |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MET 2/4885RAB9A 1750/4885MMP13 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.